Anti-Human/Mouse LY6E Antibody (9B12)
Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8+ T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8+ T cells strictly depends on the presence of PILRα, and it does not affect CD4+ T cells or T cell development in the thymus, exhibiting high specificity.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Species Reactivity
Human/Mouse
In Vitro
Anti-Human/Mouse LY6E Antibody (9B12) binds to human LY6E with an average Kd of 3.7 nmol/L and to cynomolgus monkey LY6E with an average Kd of 6.9 nmol/L[2].
Anti-Human/Mouse LY6E Antibody (9B12) (5 μg/mL; 30 min, 2 h) is internalized into KURAMOCHI ovarian cancer cells within 30 minutes (via a lipid raft-dependent, clathrin-independent pathway) and into HCC1569 breast cancer cells within 2 hours, colocalizing with lysosomal compartments in both cell types[2].
Anti-Human/Mouse LY6E Antibody (9B12) detects low, moderate, and high surface LY6E expression via flow cytometry on DOV13, COV362, and KURAMOCHI ovarian cancer cells, respectively, matching their corresponding LY6E copy numbers[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human ovarian cancer KURAMOCHI cells, human breast cancer HCC1569 cells
-
Concentration:5 μg/mL (KURAMOCHI cells)
-
Incubation Time:30 min (KURAMOCHI cells); 2 hours (HCC1569 cells)
-
Result:Was internalized into live KURAMOCHI cells within 30 minutes, colocalizing with late endosomal/lysosomal marker LAMP1.
Internalization into KURAMOCHI cells was inhibited by 1 mmol/L methyl β cyclodextrin but not by 25 μmol/L chlorpromazine.
Was endocytosed to the lysosomes of HCC1569 cells within a 2-hour period.
In Vivo
Anti-Human/Mouse LY6E Antibody (9B12) (1-6 mg/kg; i.v.; single dose) conjugated to MMAE achieves 80% partial responses with 1 month of sustained tumor regression in SW900 NSCLC xenografts, with higher doses driving sustained near-complete tumor regression[2].
Anti-Human/Mouse LY6E Antibody (9B12) (2-12 mg/kg; i.v.; single dose) conjugated to MMAE achieves 80% partial responses and 20% complete responses in PAXF 1657 pancreatic cancer patient-derived xenografts, with higher doses driving sustained near-complete tumor regression[2].
Anti-Human/Mouse LY6E Antibody (9B12) (2-12 mg/kg; i.v.; single dose) conjugated to MMAE achieves 100% complete responses in HBCx-9 triple-negative breast cancer patient-derived xenografts with heterogeneous LY6E expression, with sustained tumor regression lasting 25 days post-dose[2].
Anti-Human/Mouse LY6E Antibody (9B12) (4-12 mg/kg; i.v.; single dose) conjugated to MMAE achieves 40% partial responses in MAXF 1162 HER2-positive breast cancer patient-derived xenografts, with higher doses driving complete responses[2].
Anti-Human/Mouse LY6E Antibody (9B12) (200 μg; i.p.; every 3 to 4 days; 15 days) disrupts CD8+ T cell quiescence and reduces CD8+ T cell survival in peripheral lymphoid organs of B6 WT mice, with no effect on CD4+ T cells[3].
Anti-Human/Mouse LY6E Antibody (9B12) (200 μg; i.p.; every 3 days; 14 days) reduces CD8+ T cell survival in peripheral lymphoid organs of thymectomized B6 WT mice, confirming effects are independent of thymic T cell development[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C.B-17 SCID (female, 4-6 weeks old, subcutaneous inoculation with SU.86.86 pancreatic cancer cells)[2]
-
Dosage:0.5 mg/kg; 1 mg/kg; 2 mg/kg; 4 mg/kg; 8 mg/kg
-
Administration:i.v.; single dose
-
Result:Achieved 8 of 10 partial responses and 1 of 10 complete responses at 2 mg/kg.
Induced sustained, near-complete tumor regression through the 40-day study period at 4 mg/kg and 8 mg/kg.
-
Animal Model:C.B-17 SCID beige (female, 4-6 weeks old, subcutaneous inoculation with SW900 squamous NSCLC cells)[2]
-
Dosage:1 mg/kg; 3 mg/kg; 6 mg/kg
-
Administration:i.v.; single dose
-
Result:Achieved 8 partial responses with tumor regression lasting for about 1 month post-dose at 1 mg/kg.
Induced sustained, near-complete tumor regression through the 40-day study period at 3 mg/kg and 6 mg/kg.
Gene ID
Accession
Q16553
Target
Ly6E
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay, Research in vivo
Chemical Information
-
SMILES
[Anti-Human/Mouse LY6E Antibody (9B12)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Authier F, et al. Association of insulin-degrading enzyme with a 70 kDa cytosolic protein in hepatoma cells. Biochem J. 1996;319 ( Pt 1)(Pt 1):149-158. [Content Brief]
[2]. Asundi J, et al. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. Clin Cancer Res. 2015;21(14):3252-3262. [Content Brief]
[3]. Zheng L, et al. The CD8α-PILRα interaction maintains CD8+ T cell quiescence. Science. 2022;376(6596):996-1001. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Human/Mouse LY6E Antibody (9B12) Related Classifications
HY-P992056 Related Classifications
Powered by Bioz